Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Feb;68(2):144–149. doi: 10.1136/jnnp.68.2.144

Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life

D Parkin 1, A Jacoby 1, P McNamee 1, P Miller 1, S Thomas 1, D Bates 1
PMCID: PMC1736797  PMID: 10644777

Abstract

OBJECTIVE—To evaluate the cost-effectiveness of interferon beta-1b (IFβ-1b) for relapsing-remitting multiple sclerosis (RRMS).
METHODS—Construction of a cost-effectiveness model using published data on IFβ-1b effectiveness and the natural history of RRMS, and new data on costs and quality of life (QoL) from a sample of 102patients with RRMS and resident in northern England.
RESULTS—Poorer QoL was found for patients with multiple sclerosis compared with the general population; those who had had a relapse; those with worse states identified by a clinical measure (expanded disability status scale (EDSS)). Relapses have effects over several months. Health state valuations were higher than in the general population. Costs were higher in relapse than remission and for worse EDSS states. IFβ-1b costs were larger than cost savings. The best cost-effectiveness estimate was £28 700 per relapse avoided, which is £809 900 per QALY gained; or £328 300 per QALY gained allowing for effects of progression over 5 years. Estimates were robust to changes in assumptions.
CONCLUSIONS—The impact of multiple sclerosis on QoL is substantial. Future trials should base outcomes measurement on QoL and be better linked to natural history and cost data. IFβ-1b produces important occasional short term QoL gains, but small gains in QALYs overall and large additional costs.



Full Text

The Full Text of this article is available as a PDF (218.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
  2. Jenkinson C., Coulter A., Wright L. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 1993 May 29;306(6890):1437–1440. doi: 10.1136/bmj.306.6890.1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  4. Vickrey B. G., Hays R. D., Harooni R., Myers L. W., Ellison G. W. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995 Jun;4(3):187–206. doi: 10.1007/BF02260859. [DOI] [PubMed] [Google Scholar]
  5. Ware J. E., Jr, Sherbourne C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–483. [PubMed] [Google Scholar]
  6. Weinshenker B. G., Bass B., Rice G. P., Noseworthy J., Carriere W., Baskerville J., Ebers G. C. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989 Dec;112(Pt 6):1419–1428. doi: 10.1093/brain/112.6.1419. [DOI] [PubMed] [Google Scholar]
  7. Weinshenker B. G., Bass B., Rice G. P., Noseworthy J., Carriere W., Baskerville J., Ebers G. C. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989 Feb;112(Pt 1):133–146. doi: 10.1093/brain/112.1.133. [DOI] [PubMed] [Google Scholar]
  8. Weinshenker B. G., Rice G. P., Noseworthy J. H., Carriere W., Baskerville J., Ebers G. C. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain. 1991 Apr;114(Pt 2):1045–1056. doi: 10.1093/brain/114.2.1045. [DOI] [PubMed] [Google Scholar]
  9. Weinshenker B. G., Rice G. P., Noseworthy J. H., Carriere W., Baskerville J., Ebers G. C. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain. 1991 Apr;114(Pt 2):1057–1067. doi: 10.1093/brain/114.2.1057. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES